

## Vicore to Present at the Jefferies Global Healthcare Conference

**Stockholm, May 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Jefferies Global Healthcare Conference:**

- **Location:** New York, USA
- **Format:** Presentation and 1x1 meetings
- **Presentation Date and Time:** Thursday, June 5 at 4:20 PM ET
- **Webcast:** <https://wsw.com/webcast/jeff319/vico/1857304>
- **Participants:** Ahmed Mousa, CEO, and Megan Richards, VP of IR

The company's management will also be available for meetings at the conference. Interested parties may access the webcast replay on the [Events & Presentations](#) page of Vicore's website for 90 days following the conclusion of the event.

**For further information, please contact:**

Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [megan.richards@vicorepharma.com](mailto:megan.richards@vicorepharma.com)

Hans Jeppsson, CFO, tel: +46 70 553 14 65, [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

**About Vicore Pharma**

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

The company is publicly listed on the Nasdaq Stockholm exchange (VICO). [www.vicorepharma.com](http://www.vicorepharma.com)

**Attachments**

[Vicore to Present at the Jefferies Global Healthcare Conference](#)